Niagen (NR) is one of the most extensively studied NAD+ precursors available. Intravenous NR has been evaluated in clinical research and is generally well-tolerated, with a favorable safety profile. As with any IV therapy, a comprehensive consultation and medical assessment are recommended, and at Meeting Point Health, are conducted prior to treatment to ensure it is appropriate for you.